ACCOUNTS RECEIVABLE |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ACCOUNTS RECEIVABLE | ACCOUNTS RECEIVABLE The following table sets forth the details of the Company’s accounts receivable, net balances included on the consolidated balance sheets as of December 31, 2024 and 2023:
As of January 1, 2023, the Company’s accounts receivable balance was $44.5 million. The Company incurred bad debt expense of $1.0 million and $0.2 million, respectively, for the years ended December 31, 2024 and 2023. Write-offs were $0.7 million and immaterial for the years ended December 31, 2024 and 2023, respectively. Recoveries were immaterial for the years ended December 31, 2024 and 2023. See Note 3 — Revenue Recognition for disclosure of any concentrations in both accounts receivable and revenue.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||